Viewing Study NCT02185560


Ignite Creation Date: 2025-12-25 @ 2:13 AM
Ignite Modification Date: 2026-01-08 @ 4:24 PM
Study NCT ID: NCT02185560
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-23
First Post: 2014-07-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Sponsor: Bayer
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module